Senate Appropriations Bill Provides Boost to Fight Against AMR

IDSA is pleased to see that critical new investments to strengthen the federal fight against antimicrobial resistance were included in the fiscal year 2023 Labor, Health and Human Services appropriations bill released July 28.

IDSA Statement on Increase in Monkeypox Vaccine Supply

Today’s U.S. Department of Health and Human Services announcement that nearly 800,000 additional doses of the monkeypox vaccine are now available for distribution is a welcome development, but much more is urgently needed.

IDSA/HIVMA Support Rapid CDC Response to Monkeypox Treatment Access Issues

IDSA and HIVMA appreciate the CDC’s swift action in responding to health care provider concerns regarding the significant procedural barriers required to obtain tecovirimat, or TPOXX, through the Expanded Access for Investigational New Drug program.

Five Institutions Receive the IDSA Antimicrobial Stewardship Center of Excellence Designation

The five awarded institutions have created stewardship programs led by infectious diseases-trained physicians and pharmacists that advance science in antimicrobial resistance.

IDSA Launches Call for Applications for Next Editor-in-Chief of Open Forum Infectious Diseases

IDSA seeks candidates to serve in the position of editor-in-chief of OFID. The founding editor-in-chief of the journal, Paul Sax, MD, FIDSA, recently departed for a new role as editor-in-chief of IDSA’s journal CID.

U.S. Must Curb Rising Rate of Resistance to Antimicrobials

With rates of antimicrobial-resistant infections rising quickly, systemic changes are urgently needed to protect public health. This is no longer a future crisis but one that is at America’s doorstep and needs to be addressed now.

Paxlovid Prescribing Changes May Improve Access and Equity

FDA’s decision to authorize state-licensed pharmacists to prescribe Paxlovid, within the limitations of and for those indications stated in the emergency use authorization, has the potential to expand access to timely treatment.

House Appropriations Bills Include Increased Federal Funding for ID Programs

IDSA is pleased to see increased funding to strengthen the federal response to antimicrobial resistance, bolster the domestic and global fight against COVID-19, combat the infectious diseases impacts of the opioid crisis and strengthen global security in two recently passed appropriations bills.

IDSA Thanks Retiring Clinical Infectious Diseases Editors

As the term of Robert T. Schooley, MD, FIDSA, as editor-in-chief of Clinical Infectious Diseases ends, the Infectious Diseases Society of America wishes to thank him and all members of his editorial board for their extraordinary work as journal and Society leaders.

IDSA and HIVMA Welcome Administration’s Commitment to Bolstering Monkeypox Testing and Vaccination

Increasing access to monkeypox testing and expanding vaccination against infection to people at high risk are needed and welcome steps in efforts to control spread and minimize symptoms.

House Appropriations Bill Prioritizes Federal Response to Antimicrobial Resistance

Antimicrobial resistance — what infectious diseases experts warn could become the next pandemic — is poised to receive much needed federal investment.

Supreme Court Decision Overturning Roe v. Wade Threatens Sanctity of Provider-Patient Relationship

IDSA and HIVMA condemn the U.S. Supreme Court decision overturning Roe v. Wade that sanctions government interference in patient autonomy and care and threatens the sanctity of the provider-patient relationship.